Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64619178 in advanced cancers and MDS
NCT03573310Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of JNJ-64619178 in non-Hodgkin lymphoma (NHL), solid tumor and myelodysplastic syndrome (MDS) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Dose-limiting Toxicities at 3 years. Started Jul 2018; status: completed.
02
Drugs
JNJ-64619178
03
Conditions
non-Hodgkin lymphoma (NHL)solid tumormyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03573310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573310.